K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy

Annals of Surgical Oncology

Volumn 19, Issue SUPPL. 3, 2012, Pages

  Chen, Tse Ching ^a   Jan, Yi Yin ^a   Yeh, Ta Sen ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; K RAS PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CODON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; LASER CAPTURE MICRODISSECTION; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERINEURAL INVASION; RETROSPECTIVE STUDY;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CODON; FEMALE; GENES, RAS; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM INVASIVENESS; ODDS RATIO; PERIPHERAL NERVES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84864986059     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2224-7     Document Type: Article

References (26)

1. SA Khan HC Thomas BR Davidson, et al. 2005 Cholangiocarcinoma. Lancet. 36 1303 1314 10.1016/S0140-6736(05)67530-7
2. P Yachimski DS Pratt 2008 Cholangiocarcinoma. Natural history, treatment, and strategies for surveillance in high risk patients J Clin Gastroenterol. 42 178 190 18209589 10.1097/MCG.0b013e31806daf89
3. MF Chen YY Jan TL Hwang LB Jeng TS Yeh 2000 The impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma Dig Dis Sci. 45 312 316 10711444 10.1023/A:1005460509677 1:STN:280:DC%2BD3c7nsVGrtA%3D%3D
4. YY Jan CN Yeh TS Yeh, et al. 2005 Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital World J Gastroenterol. 11 1779 1784 15793863
5. SY Cho SJ Park SH Kim, et al. 2010 Survival analysis of intrahepatic cholangiocarcinoma after resection Ann Surg Oncol. 17 1823 1830 20165987 10.1245/s10434-010-0938-y
6. KT Nguyen J Steel T Vanounou, et al. 2009 Initial presentation of hilar and peripheral cholangiocarcinoma: is a node-positive or potential margin-positive result a contraindication to resection? Ann Surg Oncol. 16 3308 3315 19774418 10.1245/s10434-009-0701-4
7. JC Hong H Petrowsky FM Kaldas, et al. 2011 Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma J Am Coll Surg. 212 514 520 21463781 10.1016/j.jamcollsurg.2010.12.005
8. K Shirai T Ebata K Oda, et al. 2008 Perineural invasion is a prognostic factor in intrahepatic cholangiocarcinoma World J Surg. 32 2395 2402 18795245 10.1007/s00268-008-9726-2
9. Malka D, Trabach T, Fartoux L, et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. J Clin Oncol. 2009;27(Suppl 15 s; Abstract 4520).
10. B Paule MO Herelle E Rage, et al. 2007 Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas Oncology. 72 105 110 18025804 10.1159/000111117 1:CAS:528:DC%2BD2sXhtlyksLrF
11. TS Yeh JH Tseng CT Chiu, et al. 2006 Cholangiographic spectrum of intraductal papillary mucinous neoplasm of the bile ducts Ann Surg. 244 248 253 16858187 10.1097/01.sla.0000217636.40050.54
12. TS Yeh JH Tseng 2005 MD, Chen TC, et al. Characterization of intraductal growth type intrahepatic cholangiocarcinoma and its precursor Hepatology. 42 657 664 16116640 10.1002/hep.20837
13. T Kiba H Tsuda C Pairojkul, et al. 1993 Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocarcinoma in Japan and Thailand Mol Carcinog. 8 312 318 8280380 10.1002/mc.2940080415 1:CAS:528:DyaK2MXovFai
14. K Ohashi Y Nakajima H Kanehiro, et al. 1995 K-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinoma: relation to gross tumor morphology Gastroenterology. 109 1612 1617 7557145 10.1016/0016-5085(95)90650-9 1:CAS:528:DyaK28XjsVCk
15. A Tannapfel F Sommerer M Benicke, et al. 2003 Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut. 52 706 712 12692057 10.1136/gut.52.5.706 1:CAS:528:DC%2BD3sXjvVeiu7g%3D
16. A Rashid T Ueki YT Gao, et al. 2002 K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China Clin Cancer Res. 8 3156 3163 12374683 1:CAS:528: DC%2BD38XosFKhsL0%3D
17. KM Boberg E Schrumpf A Bergquist, et al. 2000 Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and P53dysfunction are implicated in the neoplastic development J Hepatol. 32 374 380 10735605 10.1016/S0168-8278(00)80386-4 1:CAS:528:DC%2BD3cXisFOnsr4%3D
18. MO Hassan 1980 The prostatic perineural space and its relation to tumor spread Am J Surg Pathol. 4 143 148 6155085 10.1097/00000478-198004000-00006 1:STN:280:DyaL3c7ps1Whtg%3D%3D
19. MR Bhuiya Y Nimura J Kamiya, et al. 1992 Clinicopathological studies of perineural invasion of bile duct carcinoma Ann Surg. 215 344 349 1558415 10.1097/00000658-199204000-00007 1:STN:280:DyaK383hsV2rtQ%3D%3D
20. M Momiyama K Wakai K Oda, et al. 2008 Lifestyle risk factors for intrahepatic stone: findings from a case-control study in an endemic area Taiwan. J Gastroenterol Hepatol. 23 1075 1081 10.1111/j.1440-1746.2007.05258.x
21. T Kokuryo T Yamamoto K Oda, et al. 2003 Profiling of gene expression with hepatolithiasis by complementary DNA expression array Int J Oncol. 22 175 179 12469201 1:CAS:528:DC%2BD3sXhsVSmsA%3D%3D
22. AE Sirica 2008 Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma World J Gastroenterol. 14 7033 7058 19084911 10.3748/wjg.14.7033 1:CAS:528:DC%2BD1MXjvFWltrw%3D
23. AF Hezel V Deshpande AX Zhu 2010 Genetics of biliary tract cancers and emerging targeted therapies J Clin Oncol. 28 3531 3540 20547994 10.1200/JCO.2009.27.4787 1:CAS:528:DC%2BC3cXhtVGisL7E
24. E Massarelli M Varella-Garcia X Tang, et al. 2007 KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res. 13 2890 2896 17504988 10.1158/1078-0432.CCR-06-3043 1:CAS:528: DC%2BD2sXlt1Krs7g%3D
25. A Lievre JB Bachet D Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res. 66 3992 3995 16618717 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D
26. C Karapetis S Khambata-Ford D Jonker, et al. 2008 K-ras mutations and benefit of cetuximab in advanced colorectal cancer N Engl J Med. 359 1 9 10.1056/NEJMoa0804385